Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04724837
Registration number
NCT04724837
Ethics application status
Date submitted
25/01/2021
Date registered
26/01/2021
Date last updated
1/09/2023
Titles & IDs
Public title
Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)
Query!
Scientific title
A Phase 2b Multicentre, Randomised, Double-Blind, Active-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients With Chronic Kidney Disease With Estimated Glomerular Filtration Rate (eGFR) = 20 mL/Min/1.73 m^2
Query!
Secondary ID [1]
0
0
2020-004101-32
Query!
Secondary ID [2]
0
0
D4325C00001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ZENITH-CKD
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Chronic Kidney Disease
0
0
Query!
Condition category
Condition code
Renal and Urogenital
0
0
0
0
Query!
Kidney disease
Query!
Renal and Urogenital
0
0
0
0
Query!
Other renal and urogenital disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Zibotentan
Treatment: Drugs - Dapagliflozin
Treatment: Drugs - Placebo
Experimental: Zibotentan Dose A + Dapagliflozin - Participants will receive once daily oral dose A of zibotentan and 10 mg dapagliflozin for 12 weeks.
Experimental: Zibotentan Dose B + Dapagliflozin - Participants will receive once daily oral dose B of zibotentan and 10 mg dapagliflozin for 12 weeks.
Experimental: Placebo + Dapagliflozin - Participants will receive once daily oral dose of dapagliflozin 10 mg and placebo for 12 weeks.
Treatment: Drugs: Zibotentan
Participants will receive zibotentan as per the arms they are randomized.
Treatment: Drugs: Dapagliflozin
Participants will receive 10 mg dapagliflozin as per the arms they are randomized.
Treatment: Drugs: Placebo
Participants will receive placebo as per the arms they are randomized to.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change in Log-transformed Urinary Albumin to Creatinine Ratio (UACR) from baseline to Week 12
Query!
Assessment method [1]
0
0
The effect of zibotentan Dose B/dapagliflozin 10 mg versus dapagliflozin 10 mg on UACR will be assessed.
Query!
Timepoint [1]
0
0
From baseline (Week 0 [Day 1]) until Week 12 (Day 84)
Query!
Secondary outcome [1]
0
0
Change in Log-transformed UACR from baseline to Week 12
Query!
Assessment method [1]
0
0
The effect of zibotentan dose A/dapagliflozin 10 mg versus dapagliflozin 10 mg monotherapy on UACR will be assessed.
Query!
Timepoint [1]
0
0
From baseline (Week 0 [Day 1]) until Week 12 (Day 84)
Query!
Secondary outcome [2]
0
0
Change in Blood Pressure from baseline to Week 12
Query!
Assessment method [2]
0
0
The change in office systolic and diastolic blood pressure (BP) for doses of zibotentan combined with dapagliflozin 10 mg versus dapagliflozin 10 mg monotherapy will be assessed.
Query!
Timepoint [2]
0
0
From baseline (Week 0 [Day 1]) until Week 12 (Day 84)
Query!
Secondary outcome [3]
0
0
Change in log-transformed UACR from baseline to Week 12
Query!
Assessment method [3]
0
0
The assessment of dose-response and relationship across different dose of zibotentan/dapagliflozin and dapagliflozin alone on UACR reduction.
Query!
Timepoint [3]
0
0
From baseline until Week 12 (Day 84)
Query!
Secondary outcome [4]
0
0
Change in eGFR from Baseline to Week 1, Week 12 and Week 14
Query!
Assessment method [4]
0
0
The effect of different doses of zibotentan and dapagliflozin 10 mg in combination versus dapagliflozin 10 mg monotherapy on eGFR will be assessed.
Query!
Timepoint [4]
0
0
From baseline (Week 0 [Day 1]) until Week 1, Week 12, and Week 14
Query!
Secondary outcome [5]
0
0
Change in eGFR from Week 1 to Week 12
Query!
Assessment method [5]
0
0
The effect of different doses of zibotentan and dapagliflozin 10 mg in combination versus dapagliflozin 10 mg monotherapy on eGFR will be assessed.
Query!
Timepoint [5]
0
0
From Week 1 (Day 8) until Week 12 (Day 84)
Query!
Secondary outcome [6]
0
0
Number of Participants Experiencing Adverse events
Query!
Assessment method [6]
0
0
The safety and tolerability of all doses of zibotentan combined with dapagliflozin 10 mg and dapagliflozin 10 mg monotherapy will be assessed.
Query!
Timepoint [6]
0
0
From Week 0 (Day 1) until Follow-up visit (Week 14 [Day 98])
Query!
Eligibility
Key inclusion criteria
Participants are eligible to be included in the study only if all of the following criteria
apply:
- Diagnosis of Chronic kidney disease (CKD), defined as:
(a) eGFR chronic kidney disease epidemiology collaboration (CKD-EPI) = 20 mL/min/1.73
m^2, and (b) UACR = 150 and = 5000 mg albumin/g creatinine, based on a single first
morning void spot urine sample at screening.
- No current or prior (within 1 month of screening) medical treatment with an SGLT2i
(sodium-glucose co-transporter 2 inhibitor) or any fixed dose combination with SGLT2i.
- If Angiotensin-converting enzyme inhibitors (ACEi) and/or Angiotensin receptor
blockers (ARB) and/or mineralocorticoid receptor agonist are prescribed, the dose must
be stable = 4 weeks before screening. Participants who have been deemed unable to
tolerate ACEi or ARB therapy due to allergy or complications can be enrolled.
- No current or prior treatment within 6 months prior to screening with cytotoxic
therapy, immunosuppressive therapy or other immunotherapy for primary or secondary
kidney disease.
- Body mass index = 40 kg/m^2.
- Male or female of non-childbearing potential.
- Female participants must have a negative pregnancy test at screening, must not be
lactating, and must be of non-childbearing potential, confirmed at screening by
fulfilling one of the following criteria:
- Postmenopausal defined as amenorrhoea for at least 12 months or more following
cessation of all exogenous hormonal treatments and follicle-stimulating hormone
and luteinizing hormone levels in the postmenopausal range.
- Documentation of irreversible surgical sterilisation by hysterectomy, bilateral
oophorectomy, or bilateral salpingectomy but not tubal ligation.
- Male participants must be surgically sterile, abstinent, or in conjunction with a
female sexual partner, using a highly effective method of contraception for the
duration of the study (from the time they sign consent) and for 3 months after the
last dose of investigational product to prevent any pregnancies. Male study
participants must not donate or bank sperm during this same time period.
- Capable of giving signed informed consent, as described in Appendix A, which includes
compliance with the requirements and restrictions listed in the informed consent form
(ICF) and in this protocol.
- Provision of signed and dated, written ICF prior to any mandatory study-specific
procedures, sampling, and analyses.
- Provision of signed and dated written Genetic informed consent prior to collection of
samples (optional) for genetic analysis.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
130
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Participants are excluded from the study if any of the following criteria apply:
- Minimal change disease, unstable rapidly progressing renal disease, and/or renal
disease requiring significant immunosuppression, autosomal dominant or autosomal
recessive polycystic kidney disease.
- Participants with New York Heart Association classification functional heart failure
(HF) class III or IV.
- Acute coronary syndrome events within 3 months prior to screening.
- Participants with a B-type natriuretic peptide (BNP) = 200 pg/mL or NT-proBNP = 600
pg/mL (BNP = 400 pg/mL or NT-proBNP = 1200 pg/mL, respectively, if associated with
atrial fibrillation) measured by local laboratory at screening (Visit 1).
- Participants with unstable HF requiring hospitalisation for optimisation of HF
treatment and/or who have not been stable on HF therapy within 6 months prior to
screening
- Heart failure due to cardiomyopathies that would primarily require other specific
treatment: eg, cardiomyopathy due to pericardial disease, amyloidosis or other
infiltrative diseases, cardiomyopathy related to congenital heart disease, primary
hypertrophic cardiomyopathy, cardiomyopathy related to toxic or infective conditions
(ie, chemotherapy, infective myocarditis, septic cardiomyopathy).
- High output HF (eg, due to hyperthyroidism or Paget's disease).
- Heart failure due to primary cardiac valvular disease/ dysfunction, severe functional
mitral or tricuspid valve insufficiency, or planned cardiac valve repair/replacement.
- Participants with uncontrolled diabetes mellitus (HbA1c > 12%).
- Participants with Type 1 diabetes mellitus.
- Hyponatremia, defined as serum Na+ < 135 mmol/L at the time of screening (Visit 1).
- Intermittent or persistent second or third degree atrioventricular block after sinus
node dysfunction, with clinically significant bradycardia or sinus pause when not
treated with pacemaker.
- Prolonged QT interval (QTcF > 470 ms) on ECG at screening (Visit 1) or randomisation
visit (Visit 2), known congenital long QT syndrome or history of QT prolongation
associated with other medications.
- History of any life-threatening cardiac dysrhythmia (continuous or paroxysmal or
uncontrolled ventricular rate in participants with atrial fibrillation or atrial
flutter).
- Cardiac surgery or non-elective percutaneous coronary interventions (PCI/TAVI) (within
3 months) or open chest coronary artery bypass grafting or valvular repair/replacement
(within 3 months) prior to screening or is planned to undergo any of these procedures
after randomisation.
- Heart transplantation or left ventricular assist device at any time.
- Kidney or any organ transplantation.
- History or ongoing allergy/hypersensitivity, as judged by the investigator, to SGLT2i
(eg, dapagliflozin, canagliflozin, empagliflozin) or drugs with a similar chemical
structure to zibotentan.
- Any clinically significant disease or disorder (eg, cardiovascular, gastrointestinal,
liver, renal, neurological, musculoskeletal, endocrine, metabolic, psychiatric, major
physical impairment), which might put the participant at risk because of participation
in the study, or probable alternative primary reason for participant's symptoms in
judgment of investigator, including but not limited to:
- Isolated pulmonary arterial hypertension [PAP] (defined as mean PAP = 25 mmHg at
rest) or right ventricular failure; in the absence of left-sided HF
- Anaemia defined as haemoglobin (Hb) level < 100 g/L or 10 g/dL at screening
(Visit 1)
- Severe chronic obstructive pulmonary disease or other lung disease including but
not limited to pulmonary fibrosis requiring chronic oxygen therapy, regular
nebuliser use, or oral steroid therapy
- Stroke, transient ischemic attack, carotid surgery, or carotid angioplasty within
previous 3 months prior to screening.
- Severe hepatic impairment (Child-Pugh class C Hepatic impairment), aspartate
transaminase or alanine transaminase > 2x the upper limit of normal [ULN]; or total
bilirubin > 2x ULN at time of screening.
- Participants with newly detected pathological laboratory values or an ongoing disease
condition requiring investigation and/or initiation or adjustment of current treatment
(in the opinion of the investigator).
- Positive hepatitis C antibody, or hepatitis B virus, surface antigen at screening.
- Positive human immunodeficiency virus (HIV) test.
- Participants treated with strong or moderate CYP3A4 inhibitor or inducer.
- Any condition outside the renal and CV disease area, such as but not limited to
malignancy, with a life expectancy of less than 2 years based on investigator's
clinical judgment.
- Confirmation of corona virus disease- 2019 (COVID-19) infection:
- Participant has a positive test result for severe acute respiratory syndrome
coronavirus 2 during screening. Participants who are not hospitalised for
COVID-19 infections can be re screened 4 weeks after they have recovered.
- Participant has been previously hospitalised with COVID-19 infection.
- Ejection fraction < 50% measured by echocardiogram at screening.
- Participation in another clinical study with an investigational product administered
in the last 3 months prior to screening.
- Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
staff and/or staff at the study site).
- Judgment by the investigator that the participant should not participate in the study
if the participant is unlikely to comply with study procedures, restrictions, and
requirements.
- Previous randomisation into the present study.
- Plasma donation within 1 month of the visit at the clinic or any blood donation/blood
loss > 500 mL during the 3 months prior to any visit at the clinic.
- Male participant in a sexually active relation with pregnant or breastfeeding partner.
- Participants can decline to participate in the genetic research and may still
participate in the study. Exclusion from this optional genetic research may be for any
of the exclusion criteria specified for the main study or any of the following:
- Previous allogeneic bone marrow transplant.
- Non-leukocyte depleted whole blood transfusion within 120 days of genetic sample
collection.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
28/04/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/06/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
542
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - Adelaide
Query!
Recruitment hospital [2]
0
0
Research Site - Birtinya
Query!
Recruitment hospital [3]
0
0
Research Site - Elizabeth Vale
Query!
Recruitment hospital [4]
0
0
Research Site - Gosford
Query!
Recruitment hospital [5]
0
0
Research Site - Westmead
Query!
Recruitment postcode(s) [1]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
4575 - Birtinya
Query!
Recruitment postcode(s) [3]
0
0
5112 - Elizabeth Vale
Query!
Recruitment postcode(s) [4]
0
0
2250 - Gosford
Query!
Recruitment postcode(s) [5]
0
0
2145 - Westmead
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Kansas
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Kentucky
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Louisiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Massachusetts
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Michigan
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Nebraska
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Nevada
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
North Carolina
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Ohio
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Pennsylvania
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Tennessee
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Texas
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Virginia
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Washington
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
Buenos Aires
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
Caba
Query!
Country [21]
0
0
Argentina
Query!
State/province [21]
0
0
Cordoba
Query!
Country [22]
0
0
Argentina
Query!
State/province [22]
0
0
Corrientes
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
Junín
Query!
Country [24]
0
0
Argentina
Query!
State/province [24]
0
0
Mar del Plata
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
San Luis
Query!
Country [26]
0
0
Argentina
Query!
State/province [26]
0
0
San Miguel de Tucuman
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
Santa Fe
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
Botucatu
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
Campinas
Query!
Country [30]
0
0
Brazil
Query!
State/province [30]
0
0
Curitiba
Query!
Country [31]
0
0
Brazil
Query!
State/province [31]
0
0
Porto Alegre
Query!
Country [32]
0
0
Brazil
Query!
State/province [32]
0
0
Santo Andre
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
Sao Paulo
Query!
Country [34]
0
0
Brazil
Query!
State/province [34]
0
0
São José do Rio Preto
Query!
Country [35]
0
0
Brazil
Query!
State/province [35]
0
0
São Paulo
Query!
Country [36]
0
0
Bulgaria
Query!
State/province [36]
0
0
Gabrovo
Query!
Country [37]
0
0
Bulgaria
Query!
State/province [37]
0
0
Kozloduy
Query!
Country [38]
0
0
Bulgaria
Query!
State/province [38]
0
0
Montana
Query!
Country [39]
0
0
Bulgaria
Query!
State/province [39]
0
0
Plovdiv
Query!
Country [40]
0
0
Bulgaria
Query!
State/province [40]
0
0
Sliven
Query!
Country [41]
0
0
Bulgaria
Query!
State/province [41]
0
0
Sofia
Query!
Country [42]
0
0
Bulgaria
Query!
State/province [42]
0
0
Stara Zagora
Query!
Country [43]
0
0
Canada
Query!
State/province [43]
0
0
Ontario
Query!
Country [44]
0
0
Croatia
Query!
State/province [44]
0
0
Pula
Query!
Country [45]
0
0
Croatia
Query!
State/province [45]
0
0
Vinkovci
Query!
Country [46]
0
0
Denmark
Query!
State/province [46]
0
0
Gentofte
Query!
Country [47]
0
0
Denmark
Query!
State/province [47]
0
0
Roskilde
Query!
Country [48]
0
0
Denmark
Query!
State/province [48]
0
0
Århus N
Query!
Country [49]
0
0
Georgia
Query!
State/province [49]
0
0
Batumi
Query!
Country [50]
0
0
Georgia
Query!
State/province [50]
0
0
Gori
Query!
Country [51]
0
0
Georgia
Query!
State/province [51]
0
0
Gurjaani
Query!
Country [52]
0
0
Georgia
Query!
State/province [52]
0
0
Kutaisi
Query!
Country [53]
0
0
Georgia
Query!
State/province [53]
0
0
Marneuli
Query!
Country [54]
0
0
Georgia
Query!
State/province [54]
0
0
Tbilisi
Query!
Country [55]
0
0
Hungary
Query!
State/province [55]
0
0
Debrecen
Query!
Country [56]
0
0
Hungary
Query!
State/province [56]
0
0
Hatvan
Query!
Country [57]
0
0
Hungary
Query!
State/province [57]
0
0
Miskolc
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Bari
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Genova
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Germaneto
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Napoli
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Pavia
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
San Giovanni Rotondo
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Chiba-shi
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Chuo-ku
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Koshigaya-shi
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Nagoya
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Naka
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Osaka-shi
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Takarazuka-shi
Query!
Country [71]
0
0
Japan
Query!
State/province [71]
0
0
Tsu-shi
Query!
Country [72]
0
0
Japan
Query!
State/province [72]
0
0
Ueda-shi
Query!
Country [73]
0
0
Japan
Query!
State/province [73]
0
0
Yao-shi
Query!
Country [74]
0
0
Malaysia
Query!
State/province [74]
0
0
Kuala Lumpur
Query!
Country [75]
0
0
Malaysia
Query!
State/province [75]
0
0
Kuantan
Query!
Country [76]
0
0
Netherlands
Query!
State/province [76]
0
0
Breda
Query!
Country [77]
0
0
Netherlands
Query!
State/province [77]
0
0
Dordrecht
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Bialystok
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Krakow
Query!
Country [80]
0
0
Poland
Query!
State/province [80]
0
0
Oswiecim
Query!
Country [81]
0
0
Poland
Query!
State/province [81]
0
0
Poznan
Query!
Country [82]
0
0
Poland
Query!
State/province [82]
0
0
Rzeszow
Query!
Country [83]
0
0
Slovakia
Query!
State/province [83]
0
0
Rimavska Sobota
Query!
Country [84]
0
0
South Africa
Query!
State/province [84]
0
0
Bellville
Query!
Country [85]
0
0
South Africa
Query!
State/province [85]
0
0
Bloemfontein
Query!
Country [86]
0
0
South Africa
Query!
State/province [86]
0
0
Durban
Query!
Country [87]
0
0
South Africa
Query!
State/province [87]
0
0
George
Query!
Country [88]
0
0
South Africa
Query!
State/province [88]
0
0
Observatory
Query!
Country [89]
0
0
South Africa
Query!
State/province [89]
0
0
Pretoria
Query!
Country [90]
0
0
South Africa
Query!
State/province [90]
0
0
Somerset West
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
A Coruna
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Barcelona
Query!
Country [93]
0
0
Spain
Query!
State/province [93]
0
0
Burela
Query!
Country [94]
0
0
Spain
Query!
State/province [94]
0
0
Madrid
Query!
Country [95]
0
0
Spain
Query!
State/province [95]
0
0
Majadahonda
Query!
Country [96]
0
0
Spain
Query!
State/province [96]
0
0
Malaga
Query!
Country [97]
0
0
Spain
Query!
State/province [97]
0
0
Palma de Mallorca
Query!
Country [98]
0
0
Spain
Query!
State/province [98]
0
0
Sevilla
Query!
Country [99]
0
0
Spain
Query!
State/province [99]
0
0
Valencia
Query!
Country [100]
0
0
Ukraine
Query!
State/province [100]
0
0
Chernivts?
Query!
Country [101]
0
0
Ukraine
Query!
State/province [101]
0
0
Dnipro
Query!
Country [102]
0
0
Ukraine
Query!
State/province [102]
0
0
Kharkiv
Query!
Country [103]
0
0
Ukraine
Query!
State/province [103]
0
0
Kyiv
Query!
Country [104]
0
0
Ukraine
Query!
State/province [104]
0
0
Ternopil
Query!
Country [105]
0
0
Ukraine
Query!
State/province [105]
0
0
Uzhhorod
Query!
Country [106]
0
0
Ukraine
Query!
State/province [106]
0
0
Vinnytsia
Query!
Country [107]
0
0
Ukraine
Query!
State/province [107]
0
0
Zaporizhia
Query!
Country [108]
0
0
Ukraine
Query!
State/province [108]
0
0
Zhytomyr
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of the study is to assess efficacy, safety and tolerability of treatment with
zibotentan and dapagliflozin in combination and dapagliflozin 10 mg as monotherapy in
participants with chronic kidney disease (CKD) with estimated glomerular filtration rate
(eGFR) = 20 mL/min/1.73 m^2, and urinary albumin to creatinine ratio (UACR) = 150 mg/g and =
5000 mg/g.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04724837
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
David C Wheeler, MB ChB, MD, FRCP
Query!
Address
0
0
Centre for Nephrology Royal Free Campus University College London Rowland Hill Street London NW3 2PF United Kingdom
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04724837
Download to PDF